MIT-born startup Elicio Therapeutics’ novel Amphiphile Technology Platform is designed to directly engage the lymphatic system in the deployment and delivery of therapeutic payloads. Chief Scientific Officer Peter DeMuth, PhD at Elicio HQ in Boston talks about how the platform works, and how it’s driving rapid clinical progress for the company’s robust pipeline of therapeutic vaccines in oncology, as a cell therapy amplifier in liquid and solid tumor indications, and in prophylactic vaccines for infectious diseases like COVID-19. Dr. DeMuth also shares his journey as a young scientific founder, how he’s managed the transition from academic scientist to the C-suite, and how he leans into his scientific training to make a killer home brew.
